I can tell you from 9 years experience calling on

I can tell you from 9 years experience calling on primary care and specialty doctors that it’s a bell curve like anything else. A select few are on the front end of medicine looking forward, studying, predicting, becoming aware of products in development like Leronlimab. They’d try it, as evidenced by our hero doctor at Montefiore. On the other end there are doctors who won’t look at or consider something “new” until it’s been on the market a long time and has proven itself among colleagues. Everyone else, the vast majority, fall in the middle. They might be aware if they’re curious by nature, but still wouldn’t try it and likely only know surface level information about it anyways. But really most are unaware. They have busy days and have to retain a massive amount of information to get them through those days. They just don’t have time to know. Until we have real awareness or a study result that people can understand, which will bring real awareness, there’s just no way anyone outside of the small number of forward-looking doctors is going to consider Leronlimab. That doesn’t mean there isn’t someone close to the president’s care who might try to champion it. There just isn’t a great chance of that happening. We used to be told in pharma that it takes something like 7 times delivering the same message to a doctor until the details really sink in. I found that to at least feel true for the vast majority of doctors.